This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Johnson & Johnson vs. Abbott Laboratories in the Battle for Emerging Market Turf

NEW YORK (TheStreet) -- Emerging market pharmaceuticals are booming. So out of Johnson & Johnson (JNJ - Get Report) and Abbott Laboratories (ABT - Get Report) , which one is best positioned to take advantage of it? 

Emerging markets spend major money on pharmaceuticals. In 2010, emerging markets spent more than Germany, France, Italy, Spain and the U.K. combined. EMs are expected to represent 30% of total pharmaceutical spending by... 2016. This all boils down to an expected growth rate of 11% to 14% per year for pharmaceutical sales in emerging markets.

China is still considered the largest emerging market, and is also expected to grow pharmaceutical sales fastest. The country is expecting 15% to 18% pharmaceutical sales growth over the next several years. Both Johnson & Johnson and Abbott Laboratories are attempting to capture this strong growth trend.

Based on my 8 rules of dividend investing (more on that below), Abbott Laboratories has the advantage, but Johnson & Johnson is a fantastic company as well. Both businesses make excellent investments for long-term oriented shareholders seeking rising income.

Johnson & Johnson is the largest publicly traded health care business in the world with a market cap of $294 billion. Abbott Laboratories is a giant multinational corporation in its own right. The company has a market cap of about $64 billion.

Abbott Laboratories generates about 60% of its pharmaceutical revenue in emerging markets today and is expected to generate more than $2.8 billion in pharmaceutical sales in emerging markets this year. By 2016, it expects to generate 75% of pharmaceutical revenue from emerging markets. Abbott Laboratories is most successful in India, where it has the most sales of any pharmaceutical company.

Johnson & Johnson generates about 20% ($1.7 billion) of its $8.5 billion in pharmaceutical sales in emerging markets. The company's overall pharmaceutical operation is larger than Abbott Laboratories, but Abbott generates more sales in emerging markets. Johnson & Johnson generates the bulk of its pharmaceutical revenue in the U.S. and developed markets, while Abbott Laboratories generates more pharmaceutical revenue from emerging markets than anywhere else.

Abbott Laboratories is specifically focused on emerging market growth, and has positioned itself to better benefit from booming emerging market pharmaceutical sales. 

Johnson & Johnson vs. Abbott Laboratories: Dividend Fundamentals

Here's how these two giant health care companies compare to each other using Ben Reynold's 8 Rules of Dividend Investing, which rank high quality dividend stocks using fundamental data. 

Johnson & Johnson has the longer dividend history, paying increasing dividends for 52 consecutive years vs. 42 consecutive years for Abbott Laboratories. Both companies' long history of consistent dividend increases shows their commitment to rewarding shareholders.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $38.90 -3.76%
JNJ $112.08 -0.36%
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs